PAMPer and tRIGer: Ligand-induced activation of RIG-I

Trends in Biochemical Sciences

Volumn 36, Issue 6, 2011, Pages 314-319

  Bowzard, J Bradford ^a   Davis, William G ^a   Jeisy Scott, Victoria ^a   Ranjan, Priya ^a   Gangappa, Shivaprakash ^a   Fujita, Takashi ^b   Sambhara, Suryaprakash ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; INTERFERON; NUCLEIC ACID; PATHOGEN ASSOCIATED MOLECULAR PATTERN; RETINOIC ACID INDUCIBLE PROTEIN I; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; CYTOKINE PRODUCTION; HUMAN; INNATE IMMUNITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; RNA VIRUS; SIGNAL TRANSDUCTION; UPREGULATION; VIRAL CLEARANCE; VIRUS IMMUNITY; VIRUS REPLICATION;

DEAD-BOX RNA HELICASES; ENZYME ACTIVATION; IMMUNITY, INNATE; INTERFERONS; LIGANDS; SIGNAL TRANSDUCTION;

RNA VIRUSES;

EID: 79958053294     PISSN: 09680004     EISSN: 09680004     Source Type: Journal    
DOI: 10.1016/j.tibs.2011.03.003     Document Type: Review

References (42)

1. Jouanguy E., et al. Human primary immunodeficiencies of type I interferons. Biochimie 2007, 89:878-883.
2. Samuel C.E. Antiviral actions of interferons. Clin. Microbiol. Rev. 2001, 14:778-809.
3. Bottazzi B., et al. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu. Rev. Immunol. 2010, 28:157-183.
4. Kumagai Y., Akira S. Identification and functions of pattern-recognition receptors. J. Allergy Clin. Immunol. 2010, 125:985-992.
5. Sato S., et al. Galectins in innate immunity: dual functions of host soluble beta-galactoside-binding lectins as damage-associated molecular patterns (DAMPs) and as receptors for pathogen-associated molecular patterns (PAMPs). Immunol. Rev. 2009, 230:172-187.
6. Parkinson T. The future of toll-like receptor therapeutics. Curr. Opin. Mol. Ther. 2008, 10:21-31.
7. Tse K., Horner A.A. Update on toll-like receptor-directed therapies for human disease. Ann. Rheum Dis. 2007, 66(Suppl. 3):iii77-iii80.
8. Besch R., et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J. Clin. Invest. 2009, 119:2399-2411.
9. Chakravarthy K.V., et al. Gold nanorod delivery of an ssRNA immune activator inhibits pandemic H1N1 influenza viral replication. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:10172-10177.
10. Kubler K., et al. Targeted activation of RNA helicase retinoic acid-inducible gene-I induces proimmunogenic apoptosis of human ovarian cancer cells. Cancer Res. 2010, 70:5293-5304.
11. Luke J.M., et al. Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine. J. Virol. 2011, 85:1370-1383.
12. Ranjan P., et al. 5'PPP-RNA induced RIG-I activation inhibits drug-resistant avian H5N1 as well as 1918 and 2009 pandemic influenza virus replication. Virol. J. 2010, 7:102.
13. Spiropoulou C.F., et al. RIG-I activation inhibits ebolavirus replication. Virology 2009, 392:11-15.
14. Ranjan P., et al. Cytoplasmic nucleic acid sensors in antiviral immunity. Trends Mol. Med. 2009, 15:359-368.
15. Hausmann S., et al. RIG-I and dsRNA-induced IFNbeta activation. PLoS ONE 2008, 3:e3965.
16. Ranjith-Kumar C.T., et al. Agonist and antagonist recognition by RIG-I, a cytoplasmic innate immunity receptor. J. Biol. Chem. 2009, 284:1155-1165.
17. Uzri D., Gehrke L. Nucleotide sequences and modifications that determine RIG-I/RNA binding and signaling activities. J. Virol. 2009, 83:4174-4184.
18. Yoneyama M., et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 2004, 5:730-737.
19. Kato H., et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J. Exp. Med. 2008, 205:1601-1610.
20. Hornung V., et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006, 314:994-997.
21. Pichlmair A., et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science 2006, 314:997-1001.
22. Kato H., et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006, 441:101-105.
23. Loo Y.M., et al. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J. Virol. 2008, 82:335-345.
24. Cazenave C., Uhlenbeck O.C. RNA template-directed RNA synthesis by T7 RNA polymerase. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:6972-6976.
25. Triana-Alonso F.J., et al. Self-coded 3'-extension of run-off transcripts produces aberrant products during in vitro transcription with T7 RNA polymerase. J. Biol. Chem. 1995, 270:6298-6307.
26. Schlee M., et al. Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity 2009, 31:25-34.
27. Schmidt A., et al. 5'-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:12067-12072.
28. Cui S., et al. The C-terminal regulatory domain is the RNA 5'-triphosphate sensor of RIG-I. Mol. Cell 2008, 29:169-179.
29. Takahasi K., et al. Solution structures of cytosolic RNA sensors MDA5 and LGP2 C-terminal domains: Identification of the RNA recognition loop in RIG-I like receptors. J. Biol. Chem. 2009, 284:17465-17474.
30. Takahasi K., et al. Nonself RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune responses. Mol. Cell 2008, 29:428-440.
31. Lu C., et al. Crystal structure of RIG-I C-terminal domain bound to blunt-ended double-strand RNA without 5' triphosphate. Nucleic Acids Res. 2010, 39:1565-1575.
32. Wang Y., et al. Structural and functional insights into 5'-ppp RNA pattern recognition by the innate immune receptor RIG-I. Nat. Struct. Mol. Biol. 2010, 17:781-787.
33. Lu C., et al. The structural basis of 5' triphosphate double-stranded RNA recognition by RIG-I C-terminal domain. Structure 2010, 18:1032-1043.
34. Cheng G., et al. Double-stranded DNA and double-stranded RNA induce a common antiviral signaling pathway in human cells. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:9035-9040.
35. Ablasser A., et al. RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat. Immunol. 2009, 10:1065-1072.
36. Chiu Y.H., et al. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 2009, 138:576-591.
37. Malathi K., et al. RNase L releases a small RNA from HCV RNA that refolds into a potent PAMP. RNA 2010, 16:2108-2119.
38. Marq, J.B. et al. Short dsRNAs with an overhanging 5 prime ppp-nucleotide, as found in arenavirus genomes, act as RIG-I decoys. J. Biol. Chem. 286, 6108-16.
39. Marq J.B., et al. Unpaired 5' ppp-nucleotides, as found in arenavirus double-stranded RNA panhandles, are not recognized by RIG-I. J. Biol. Chem. 2010, 285:18208-18216.
40. Baum A., et al. Preference of RIG-I for short viral RNA molecules in infected cells revealed by next-generation sequencing. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:16303-16308.
41. Rehwinkel J., et al. RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell 2010, 140:397-408.
42. Perez J.T., et al. Influenza A virus-generated small RNAs regulate the switch from transcription to replication. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:11525-11530.